Granules India Gagillapur Facility Receives Eleven USFDA Form 483 Observations
Granules India Ltd 路 Press Release 路 31 Oct 2026, 4:17 am
Granules India Gagillapur Facility Receives Eleven USFDA Form 483 Observations The USFDA concluded a cGMP inspection at Granules India's Gagillapur finished dosage facility on 30th Oct'26, issuing a Form 483 with 11 observations. This marked the site's first inspection since receiving a Warning Letter on 26th Feb'25. Observations relate to investigations, change control, equipment qualification, visual inspection, and documentation practices, with zero issues concerning data integrity or cross-contamination. Current manufacturing and distribution remain unaffected, and the company plans to submit its comprehensive response within the mandated 15 business days.
Original exchange filing (PDF)
More announcements from Granules India Ltd
- Schedule of Investor Meet 路 11 Nov 2026
- Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA) 路 06 Nov 2026
- Transcript of the Earnings Conference Call for Q2 and the half year of FY27 路 06 Nov 2026
- Audio recording of the Earnings Conference call for Q2 and the half -year of FY27 路 03 Nov 2026
- Monitoring Agency Report for the quarter ended on September 30, 2026 路 02 Nov 2026
- Investor Presentation to Analysts/Investors 路 02 Nov 2026
- Press Release 路 02 Nov 2026
- Unaudited financial results for the second quarter and half year ended on September 30,2026 路 02 Nov 2026
